Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Frederik PerssonThomas NyströmMarit E JørgensenBendix CarstensenHanne L GulsethMarcus ThuressonPeter FeniciDavid NathansonJan W ErikssonAnna NorhammarJohan BodegardKåre I BirkelandPublished in: Diabetes, obesity & metabolism (2017)
Dapagliflozin was associated with lower risks of CV events and all-cause mortality compared with DPP-4 inhibitors in a real-world clinical setting and a broad T2D population.